Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|June 3, 2009
CADASIL and ALS: a link?Julien Praline, Nadege Limousin, Patrick Vourc'h, et al.Biomedicines|October 27, 2022
T Lymphocyte Serotonin 5-HT<sub>7</sub> Receptor Is Dysregulated in Natalizumab-Treated Multiple Sclerosis PatientsFlora Reverchon, Colleen Guillard, Lucile Mollet, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 4, 2018
Co-occurrence of MS and ALS: a clue in favor of common pathophysiological findings?Anne-Marie Guennoc, Maud Pallix-Guyot, Emmanuelle Le Page, et al.Neurology(R) Neuroimmunology & Neuroinflammation|August 28, 2019
Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitorsAlberto Vogrig, Marine Fouret, Bastien Joubert, et al.Neurology(R) Neuroimmunology & Neuroinflammation|July 11, 2024
Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: A Multicenter Cohort StudyJulie C Blant, Nicola N De Rossi, Ralf Gold, et al.Neurology(R) Neuroimmunology & Neuroinflammation|February 20, 2026
Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments: A Multicenter Cohort StudyJulie Céline Blant, Nicola De Rossi, Ralf Gold, et al.Journal for Immunotherapy of Cancer|December 5, 2019
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive studyGuillaume Manson, Alexandre Thibault Jacques Maria, Florence Poizeau, et al.JAMA Neurology|June 27, 2020
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple SclerosisCéline Louapre, Nicolas Collongues, Bruno Stankoff, et al.Pageof 1